Coherus BioSciences (CHRS) Competitors $1.39 -0.03 (-2.11%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CHRS vs. QURE, ETNB, CRMD, CGEM, PHAR, ABUS, IMNM, LENZ, EOLS, and AUTLShould you be buying Coherus BioSciences stock or one of its competitors? The main competitors of Coherus BioSciences include uniQure (QURE), 89bio (ETNB), CorMedix (CRMD), Cullinan Therapeutics (CGEM), Pharming Group (PHAR), Arbutus Biopharma (ABUS), Immunome (IMNM), LENZ Therapeutics (LENZ), Evolus (EOLS), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry. Coherus BioSciences vs. uniQure 89bio CorMedix Cullinan Therapeutics Pharming Group Arbutus Biopharma Immunome LENZ Therapeutics Evolus Autolus Therapeutics uniQure (NASDAQ:QURE) and Coherus BioSciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership. Is QURE or CHRS more profitable? Coherus BioSciences has a net margin of -0.15% compared to uniQure's net margin of -837.80%. Coherus BioSciences' return on equity of 0.00% beat uniQure's return on equity.Company Net Margins Return on Equity Return on Assets uniQure-837.80% -188.82% -32.17% Coherus BioSciences -0.15%N/A -24.44% Which has more volatility and risk, QURE or CHRS? uniQure has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Coherus BioSciences has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Which has better earnings and valuation, QURE or CHRS? Coherus BioSciences has higher revenue and earnings than uniQure. Coherus BioSciences is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatiouniQure$15.84M43.23-$308.48M-$4.96-2.83Coherus BioSciences$257.24M0.62-$237.89M-$0.08-17.38 Do analysts recommend QURE or CHRS? uniQure currently has a consensus target price of $33.88, indicating a potential upside of 141.10%. Coherus BioSciences has a consensus target price of $5.38, indicating a potential upside of 286.69%. Given Coherus BioSciences' higher possible upside, analysts plainly believe Coherus BioSciences is more favorable than uniQure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score uniQure 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00Coherus BioSciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Do insiders and institutionals believe in QURE or CHRS? 78.8% of uniQure shares are owned by institutional investors. Comparatively, 72.8% of Coherus BioSciences shares are owned by institutional investors. 4.7% of uniQure shares are owned by company insiders. Comparatively, 7.6% of Coherus BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor QURE or CHRS? uniQure received 206 more outperform votes than Coherus BioSciences when rated by MarketBeat users. Likewise, 70.67% of users gave uniQure an outperform vote while only 65.26% of users gave Coherus BioSciences an outperform vote. CompanyUnderperformOutperformuniQureOutperform Votes65370.67% Underperform Votes27129.33% Coherus BioSciencesOutperform Votes44765.26% Underperform Votes23834.74% Does the media favor QURE or CHRS? In the previous week, uniQure and uniQure both had 2 articles in the media. uniQure's average media sentiment score of 0.96 beat Coherus BioSciences' score of 0.62 indicating that uniQure is being referred to more favorably in the media. Company Overall Sentiment uniQure Positive Coherus BioSciences Positive SummaryuniQure and Coherus BioSciences tied by winning 9 of the 18 factors compared between the two stocks. Get Coherus BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRS vs. The Competition Export to ExcelMetricCoherus BioSciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$169.36M$2.96B$5.23B$8.96BDividend YieldN/A1.94%5.13%4.04%P/E Ratio-17.3841.4783.3616.84Price / Sales0.62265.171,257.9179.09Price / CashN/A192.9043.8235.97Price / Book-0.803.965.324.79Net Income-$237.89M-$41.02M$122.78M$224.99M7 Day Performance-5.44%-1.76%-0.20%1.50%1 Month Performance-11.46%0.51%3.71%4.68%1 Year Performance-42.08%-1.71%27.30%20.92% Coherus BioSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHRSCoherus BioSciences3.8034 of 5 stars$1.39-2.1%$5.38+286.7%-43.5%$169.36M$257.24M-17.38330QUREuniQure4.0289 of 5 stars$13.68-1.2%$33.88+147.6%+146.9%$666.80M$28.59M-2.76500Short Interest ↓ETNB89bio1.9082 of 5 stars$6.24-4.1%$30.33+386.1%-44.6%$662.23MN/A-2.1440Short Interest ↑News CoverageCRMDCorMedix2.4087 of 5 stars$10.87-2.9%$15.67+44.1%+263.3%$659.56M$12.26M-13.4230CGEMCullinan Therapeutics2.4039 of 5 stars$10.81-3.4%$31.67+192.9%-1.3%$629.45M$18.94M-3.8130PHARPharming Group2.5788 of 5 stars$9.14-5.9%$27.00+195.4%-19.4%$620.01M$285.75M-35.15280Short Interest ↑Positive NewsGap DownABUSArbutus Biopharma2.7209 of 5 stars$3.26-0.9%$5.50+68.7%+41.0%$617.74M$6.74M-7.5873Positive NewsIMNMImmunome1.6477 of 5 stars$9.89-6.7%$28.83+191.5%-28.6%$617.30M$10.13M-1.2240Short Interest ↑News CoveragePositive NewsGap DownLENZLENZ Therapeutics1.8581 of 5 stars$22.33-3.8%$35.40+58.5%N/A$614.10MN/A0.00110Short Interest ↑Positive NewsEOLSEvolus3.9994 of 5 stars$9.69-3.1%$23.00+137.4%-15.8%$613.58M$248.33M-10.65170Positive NewsAUTLAutolus Therapeutics3.1621 of 5 stars$2.29-3.0%$10.40+354.1%-65.8%$609.36M$10.09M-1.89330Short Interest ↑News CoverageGap Down Related Companies and Tools Related Companies uniQure Alternatives 89bio Alternatives CorMedix Alternatives Cullinan Therapeutics Alternatives Pharming Group Alternatives Arbutus Biopharma Alternatives Immunome Alternatives LENZ Therapeutics Alternatives Evolus Alternatives Autolus Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CHRS) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coherus BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CHRS Stock Alerts